Elizabeth Hexner, MD, MS, presents four case studies representing patients with the myeloproliferative disorders polycythemia vera, thrombocythemia, mast cell disease and myelofibrosis. In addition to providing background on these rare disorders, Dr. Hexner discusses standard treatment options, novel and investigational therapies and prognostic evaluation.
Related Links
- MAGE-A3/6 and NY-ESO-1 immunotherapy administered post-ASCT in patients with advanced myeloma
- Clinical Trial: A Pilot Phase I/II, Dual-Cohort, Two-Site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous Tcells Expressing a High Affinity TCR Specific for MAGE-A3/6 or NY-ESO-1 Administered Post ASCT in Patients With Adv
- Dr Hexner’s Profile
Published
August 14, 2014
Created by
BROADCASTMED